Astrocast (a form of Montelukast) is a prescription medicine utilized for managing specific respiratory and allergy-related conditions. It is indicated for the long-term management and prevention of symptoms associated with asthma in adults and pediatric patients. This includes supporting the management of breathing difficulties, coughing, and wheezing.

Additionally, the medication is an appropriate option for use in addressing the symptoms of allergic rhinitis, encompassing both seasonal (hay fever) and perennial forms. These therapeutic applications include addressing nasal symptoms such as sneezing, congestion, and runny nose that are related to environmental allergens. Astrocast may also be used to help reduce the potential for exercise-induced bronchoconstriction (airway narrowing triggered by physical activity) in certain individuals. It is intended to support the overall control of the condition, not for immediate symptom relief.

Quick Facts: Uses of Astrocast

• Long-term support for asthma symptoms.
• Management of symptoms associated with seasonal and perennial allergic rhinitis.
• Support for reducing the potential for exercise-induced airway narrowing.
• Appropriate option for use in pediatric and adult populations for specified indications.

Regulatory References

1. NIH MedlinePlus guidance

Astrocast, containing the active ingredient Montelukast, is subject to specific regulatory eligibility rules that define its use across different populations.

Contraindications and Restrictions

The medicine is contraindicated in patients with a known history of hypersensitivity to Montelukast or any component of its formulation. Furthermore, it must not be used to treat a sudden or acute asthma attack, as it is indicated only for chronic, long-term management.

Classification	Regulatory Statement
Absolute Contraindication	Hypersensitivity to the active ingredient.
Prohibited Use Context	Treatment of acute asthma exacerbations.

Age-Related Eligibility

The minimum approved age for use varies significantly by the condition being treated, based on regulatory evaluation of safety and efficacy:

• Asthma: Approved for patients 12 months of age and older.
• Perennial Allergic Rhinitis: Approved for patients 6 months of age and older.
• Seasonal Allergic Rhinitis: Approved for patients 2 years of age and older.
• Exercise-Induced Bronchoconstriction (EIB): Approved for patients 6 years of age and older.

Conditional Use and Cautions

Regulators require special caution in certain populations. Use in patients with a history of neuropsychiatric events is monitored due to potential behavioral changes. The drug is categorized for use in pregnancy and during lactation only if it is determined to be clearly necessary.

Astrocast Interactions with other medicines and products

Interaction Scope

The official interaction profile for Astrocast (Budesonide) is primarily defined by the metabolism of its active ingredient.

Property	Description
Medicinal product categories with documented interactions:	Strong inhibitors and inducers of the Cytochrome P450 3A4 (CYP3A4) enzyme.
Specific interacting medicines (if explicitly listed):	Potent inhibitors such as Ketoconazole, Itraconazole, Ritonavir, and Cobicistat-containing products are cited as increasing exposure.
Mechanistic basis of interactions (only if stated in label):	Pharmacokinetic interaction where Astrocast is a substrate of CYP3A4; inhibition of this enzyme decreases clearance.
Timing-based interaction rules (if applicable):	Consumption of Grapefruit or Grapefruit juice must be avoided for the duration of therapy.
Population-specific interaction notes (if applicable):	Use is not recommended in patients with severe hepatic impairment (Child-Pugh Class C) due to demonstrated increased systemic availability.
Interaction-related restrictions:	Co-treatment with potent CYP3A4 inhibitors should be avoided unless the benefits significantly outweigh the increased risk of systemic corticosteroid adverse reactions.

---

Interaction Classifications (High-Level)

Classification	Description
Interaction severity classification (as defined in official documents):	Clinically significant, leading to a documented several-fold increase in the drug's systemic plasma concentrations.
Regulatory basis (EMA / FDA / etc.):	Primarily documented in FDA Prescribing Information and aligned SmPC data, citing the enzyme inhibition pathway.

---

Resulting Interaction Structure

Official interaction statements:

• Co-administration with strong CYP3A4 inhibitors results in a notable increase in the systemic exposure of Astrocast.
• Official regulatory data documents that co-administration with Ketoconazole can increase Budesonide exposure by up to eight-fold.
• Grapefruit juice consumption is restricted because it inhibits intestinal CYP3A4, which approximately doubles the systemic exposure of the drug.
• Patients with moderate to severe hepatic impairment must be monitored for increased signs of systemic effects due to reduced elimination.

Connection to the overall interaction profile:

Regulatory documents define Astrocast's interaction profile based on pharmacokinetic constraints, specifically its high dependence on the CYP3A4 enzyme for metabolic clearance. This dependence requires formal avoidance advisories for strong metabolic inhibitors and a strict dietary restriction against Grapefruit products. The interaction structure necessitates specific consideration and avoidance in populations with impaired hepatic function, where drug elimination is naturally reduced.

How Astrocast Works: Mechanism of Action

The mechanism of action for Astrocast (Budesonide) centers on the targeted modulation of the inflammatory cascade at the fundamental biological level.

---

Core Mechanism: Targeting the Glucocorticoid Receptor

Astrocast functions as an agonist by binding with high affinity to the intracellular Glucocorticoid Receptor ( GR) ( NR3C1), the primary molecular target mediating its steroid activity. This interaction initiates a genomic cascade, where the drug-receptor complex translocates into the cell nucleus to modulate gene expression. By initiating this molecular sequence, the drug engages a central pathway that controls the cell's long-term synthesis of inflammatory and anti-inflammatory proteins.

---

Physiological Consequence: Modulating Inflammatory Cascades

The genomic action simultaneously executes transrepression—diminishing the transcription of genes responsible for pro-inflammatory mediators like Cytokines and Prostaglandins—and transactivation—upregulating the expression of anti-inflammatory proteins. This dual mechanism causes a reduction in inflammatory signaling molecules, which in turn attenuates the recruitment (migration) of immune cells, such as Eosinophils, to the tissue. The resulting physiological effect is the attenuation of localized vascular changes and a decrease in tissue edema, establishing a modulated physiological environment within the affected tissues.

Astrocast (Montelukast) is administered exclusively via the oral route using specialized forms, including film-coated tablets, chewable tablets, and oral granules. The medicine is intended for chronic, long-term management and is structured around a fixed, once-daily schedule.

Standard Dosing and Timing

For adults and adolescents aged 15 years and older, the standard daily maintenance dose is 10 mg. Pediatric patients are prescribed tiered doses based on age: those 6 to 14 years are typically prescribed 5 mg chewable tablets, while those 2 to 5 years receive 4 mg strength. The dose should generally be taken in the evening when used for asthma or perennial allergic rhinitis, regardless of mealtimes, as it may be taken with or without food. Dosage adjustments are not required for patients with renal impairment or mild to moderate hepatic impairment.

Special Administration Constraints

When the drug is used for the prevention of exercise-induced bronchoconstriction, a single dose must be taken at least two hours before the activity; this dose should not be taken within 24 hours of the regular daily maintenance dose. Chewable tablets must be chewed thoroughly before swallowing. If using oral granules, the entire dose must be consumed within 15 minutes of opening the sachet to ensure the correct dosage. If a daily dose is missed, it is generally advised not to take a double dose; the patient should simply resume the regular schedule the following day.

Astrocast: Recent Clinical Evidence

Evidence for Respiratory and Nasal Conditions

Research exploring how symptoms change over time for the persistent management of asthma was studied primarily through Randomized Controlled Trials (RCTs) and Real-World Observational Studies in adults and adolescents. Studies monitored functional outcomes like lung function (FEV1) and examined patterns related to the frequency of asthma exacerbations and rescue medication use. Research for the nasal spray formulation was evaluated in short-term, placebo-controlled RCTs, assessing symptoms and physiological measures in adults and children with allergic rhinitis. While findings describe observed patterns, evidence for the monotherapy in asthma is less characterized in recent literature, and comparative evidence for the nasal spray remains limited.

Evidence for Localized Inflammatory Bowel Disease

Research on Gastrointestinal Conditions

The specialized oral formulations of Astrocast were studied for conditions presenting with cycles of stability and flare-ups, specifically in the gastrointestinal tract. Evidence for Crohn's disease was evaluated in RCTs focusing on clinical status during the short-term induction phase in patients with disease localized to the terminal ileum and/or ascending colon. Similarly, Phase III RCTs monitored the evaluation of status against criteria for clinical and endoscopic remission in active, mild-to-moderate Ulcerative Colitis using colonic-targeted formulations. Data show patterns related to these specific induction phases, but certainty remains low regarding its role when compared to some other treatments, and results apply only to the specified locations.

Long-Term Data and Research Gaps

Studies exploring how symptoms change over time are key, but long-term effects are not fully established; research is ongoing. There is limited information regarding the durability of response and the prevention of recurrence across all indications. Data for certain special groups, such as children (particularly for the IBD indications) or older adults, remain insufficient, as initial trials focused on specific adult populations. Follow-up durations were limited across many trials, particularly those focusing on inflammatory bowel disease, and comparative evidence is lacking for certain treatment scenarios.

Key Studies & References

1. Budesonide - StatPearls - NCBI Bookshelf - NIH
2. Budesonide: MedlinePlus Drug Information (General Pharmacokinetics and Uses)
3. Public Assessment Report Scientific discussion Cortiment 9 mg, prolonged-release tablets (budesonide) - CBG-Meb/EMA

Common questions about Astrocast (FAQ)

---

Q: What is the difference between Astrocast and other similar medications people mention?

A: Astrocast is classified as a glucocorticoid (a type of corticosteroid). A key characteristic described in official documents is its extensive first-pass metabolism in the liver. This rapid inactivation is a factor that supports local action on inflamed tissue, which is associated with minimizing widespread systemic exposure.

---

Q: What are the most common side effects of Astrocast reported in studies?

A: According to the official product information and clinical studies, common side effects (occurring in 1% to 10% of patients) may include headache, nausea, abdominal pain, and fatigue. The official documentation also includes a decrease in blood cortisol levels as a common finding.

---

Q: Why does the official documentation mention a risk of drowsiness with Astrocast?

A: Regulatory documentation notes that adverse reactions have been documented within the Nervous System disorders and Psychiatric disorders categories. These classifications include a range of effects on mental state and alertness, which may include feeling tired or drowsy.

---

Q: Can Astrocast be taken alongside vitamin supplements?

A: The official interaction profile primarily focuses on avoiding strong inhibitors or inducers of the CYP3A4 enzyme, as these can change how much medicine is in the body. Most common vitamins and non-CYP-metabolized supplements are generally not cited in regulatory documents as interacting agents.

---

Q: Does Astrocast have a boxed warning, and what is it for?

A: Official regulatory labeling documents serious risks related to the drug's corticosteroid class, including Adrenal Axis Suppression and features of Hypercorticism. These risks are the focus of serious regulatory warnings and precautions documented on the label.

---

Q: Does Astrocast interact with common herbal supplements like St. John's Wort?

A: Regulatory documents specifically caution against co-administration with strong inhibitors or inducers of the CYP3A4 enzyme. The use of St. John’s Wort is a restriction, as it is understood to be a strong inducer of the enzyme required for drug clearance.

---

Q: Is Astrocast used for conditions other than the main one listed?

A: Yes, official regulatory approval documents show that Astrocast is used for the long-term management of specific respiratory conditions like asthma and rhinitis. It is also approved for managing localized inflammatory conditions in the gastrointestinal tract, such as Crohn's disease and Ulcerative Colitis.

---

Q: What if someone forgets to take Astrocast for a few days?

A: Official regulatory instructions for this chronic, once-daily medicine advise that if a regular dose is missed, the patient should simply resume their regular schedule on the following day. This guideline supports the management of temporary lapses in the long-term regimen. Regulatory instructions advise against taking a double dose.

---

Q: Does Astrocast cause weight gain or weight loss?

A: Due to the drug's classification as a glucocorticoid, official adverse reaction profiles include documented risks for endocrine-related effects. While specific weight change figures vary, weight changes are commonly associated with this drug class and may be listed in the full adverse reaction profile.

---

Q: Can people with liver problems use Astrocast?

A: Official regulatory guidance states that dosage adjustment is not required for patients with mild to moderate liver impairment. However, use is not recommended for patients with severe liver impairment (Child-Pugh Class C), as reduced metabolism increases the risk of higher systemic exposure.

---

Q: Can people with kidney problems use Astrocast?

A: According to the official product information, dosage adjustments are not required for patients who have renal (kidney) impairment.

---

Q: How is Astrocast thought to be different from older treatments for the same condition?

A: Regulatory documents classify Astrocast as a potent glucocorticoid that acts locally to manage inflammation. Its unique feature is its extensive first-pass metabolism, which differentiates it from older systemic steroid treatments by limiting systemic exposure.

---

Q: Is Astrocast safe to use during pregnancy?

A: Regulatory documents state that the drug is to be used during pregnancy only if it has been determined that the potential benefit justifies the potential risk. Use is based on a healthcare professional’s determination of whether the potential benefit justifies the potential risk.

---

Q: Is Astrocast safe to use while breastfeeding?

A: Official regulatory information states that the drug is to be used during lactation only if it is determined to be clearly necessary. This is based on regulatory requirements for professional evaluation of the benefits compared to potential risks.

---

Q: Can Astrocast affect sleep patterns?

A: Yes, the official safety profile includes documented adverse reactions within the Psychiatric disorders and Nervous System disorders categories. These categories commonly include sleep-related issues such as insomnia, vivid dreams, or other sleep disturbances.

---

Q: Is it safe to drive or operate machinery while taking Astrocast?

A: Official regulatory documents advise caution regarding driving or operating complex machinery. The official warning is based on the potential for side effects, such as fatigue or dizziness, that may influence the ability to drive or operate machinery.

---

Q: Is Astrocast intended to be used alone or in combination with other treatments?

A: The regulatory indications describe Astrocast's use in various treatment plans. It may be used as a monotherapy (by itself) for certain specific conditions or as part of a combination regimen for the chronic management of other conditions.

---

Q: Is it common to feel a little dizzy when first starting Astrocast?

A: While the list of most common side effects is defined, the safety profile documents adverse reactions that fall under the Nervous System disorders category. Feeling dizzy or lightheaded is a recognized type of nervous system disorder.

---

Q: Why is 'discontinuation syndrome' sometimes discussed with drugs like Astrocast?

A: Due to the potential for Adrenal Axis Suppression associated with this class of medicine (glucocorticoid), official regulatory documents indicate that gradual withdrawal is necessary to help prevent withdrawal symptoms or a discontinuation syndrome.

---

Q: How is Astrocast removed from the body?

A: The drug is removed through metabolic clearance, a process that primarily takes place in the liver. This relies on the Cytochrome P450 3A4 (CYP3A4) enzyme to break down the medicine.

How to Store and Dispose of Astrocast

Storage of Astrocast (Budesonide) must strictly adhere to regulatory labeling to maintain product stability and safety. The medicine must be kept at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F). The product must be protected from light and moisture and should be stored in its original container with the cap tightly closed.

Crucially, liquid forms, such as the nebulization suspension, must not be frozen, and any opened single-use suspension must be discarded immediately if not entirely used.

To prevent accidental ingestion, Astrocast must be stored out of the sight and reach of children.

Disposal of unused or expired medicine must comply with environmental guidelines. The medication should be returned to an authorized drug take-back program. It must not be disposed of in wastewater or thrown into household trash unless specific instructions are followed.